Wall Street analysts expect Mesa Laboratories, Inc. (NASDAQ:MLAB – Get Rating) to post earnings per share of $1.88 for the current quarter, according to Zacks. Three analysts have issued estimates for Mesa Laboratories’ earnings, with estimates ranging from $1.80 to $2.03. Mesa Laboratories reported earnings per share of $1.98 during the same quarter last year, which would indicate a negative year over year growth rate of 5.1%. The business is scheduled to issue its next earnings report on Monday, January 1st.
According to Zacks, analysts expect that Mesa Laboratories will report full year earnings of $7.01 per share for the current year. For the next fiscal year, analysts expect that the company will post earnings of $8.36 per share, with EPS estimates ranging from $6.52 to $11.05. Zacks’ EPS calculations are a mean average based on a survey of sell-side analysts that follow Mesa Laboratories.
Several brokerages recently issued reports on MLAB. Zacks Investment Research lowered shares of Mesa Laboratories from a “buy” rating to a “hold” rating in a research note on Wednesday, April 6th. StockNews.com initiated coverage on Mesa Laboratories in a report on Thursday, March 31st. They set a “hold” rating on the stock.
A number of hedge funds have recently modified their holdings of the stock. BlackRock Inc. increased its holdings in Mesa Laboratories by 0.4% during the first quarter. BlackRock Inc. now owns 924,948 shares of the medical instruments supplier’s stock valued at $235,751,000 after buying an additional 4,061 shares during the period. Conestoga Capital Advisors LLC increased its holdings in Mesa Laboratories by 1.3% during the first quarter. Conestoga Capital Advisors LLC now owns 523,571 shares of the medical instruments supplier’s stock valued at $133,448,000 after buying an additional 6,752 shares during the period. Royce & Associates LP increased its holdings in Mesa Laboratories by 4.1% during the first quarter. Royce & Associates LP now owns 356,643 shares of the medical instruments supplier’s stock valued at $90,901,000 after buying an additional 13,885 shares during the period. Vanguard Group Inc. increased its holdings in Mesa Laboratories by 1.3% during the first quarter. Vanguard Group Inc. now owns 341,492 shares of the medical instruments supplier’s stock valued at $87,040,000 after buying an additional 4,464 shares during the period. Finally, Invesco Ltd. grew its holdings in Mesa Laboratories by 0.7% in the first quarter. Invesco Ltd. now owns 277,550 shares of the medical instruments supplier’s stock worth $70,742,000 after purchasing an additional 1,898 shares during the last quarter. 91.90% of the stock is currently owned by institutional investors.
Shares of Mesa Laboratories stock traded down $1.93 during trading on Friday, reaching $210.24. The company’s stock had a trading volume of 417 shares, compared to its average volume of 32,509. The firm’s 50-day moving average is $240.17 and its two-hundred day moving average is $276.57. Mesa Laboratories has a 52-week low of $210.11 and a 52-week high of $333.42. The company has a quick ratio of 2.08, a current ratio of 2.59 and a debt-to-equity ratio of 0.58. The company has a market cap of $1.10 billion, a price-to-earnings ratio of 147.02 and a beta of 0.54.
The firm also recently declared a quarterly dividend, which will be paid on Wednesday, June 15th. Investors of record on Tuesday, May 31st will be issued a $0.16 dividend. This represents a $0.64 dividend on an annualized basis and a dividend yield of 0.30%. The ex-dividend date of this dividend is Friday, May 27th. Mesa Laboratories’s payout ratio is 44.76%.
Mesa Laboratories Company Profile (Get Rating)
Mesa Laboratories, Inc designs, manufactures, and markets quality control instruments and disposable products in the United States, Europe, Asia, North America, and internationally. The company's Sterilization and Disinfection Control segment manufactures and sells biological, cleaning, and chemical indicators that are used to assess the effectiveness of sterilization and disinfection processes in the hospital, dental, medical device, and pharmaceutical industries.
- Get a free copy of the StockNews.com research report on Mesa Laboratories (MLAB)
- 3 Retailers That Defied First Quarter Headwinds
- Will John Deere’s Earnings Help to Calm the Markets?
- Rapid7: Could Be Profitable in FY 2022 Despite Bear Market
- Lowe’s Companies Has Not Bottomed
- Silicon Labs Stock is Falling to a Better Place
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Mesa Laboratories Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mesa Laboratories and related companies with MarketBeat.com's FREE daily email newsletter.